Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.

Chen B, Wei P, Macapinlac HA, Lu Y.

Nucl Med Commun. 2019 Sep;40(9):940-946. doi: 10.1097/MNM.0000000000001051.

PMID:
31343613
2.

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.

Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V.

ESMO Open. 2019 Feb 28;4(1):e000439. doi: 10.1136/esmoopen-2018-000439. eCollection 2019.

3.

Correlation of fluorine 18-labeled sodium fluoride uptake and arterial calcification on whole-body PET/CT in cancer patients.

Dai D, Chuang HH, Macapinlac HA, Li T, Pan T.

Nucl Med Commun. 2019 Jun;40(6):604-610. doi: 10.1097/MNM.0000000000000986.

PMID:
30688757
4.

Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.

Chen B, Macapinlac HA, Lu Y.

Clin Nucl Med. 2019 Apr;44(4):337-338. doi: 10.1097/RLU.0000000000002478.

PMID:
30688749
5.

Prognostic Impact of FDG-PET/CT Images in Patients With Suspected Cardiac Sarcoidosis: Optimal Patient Preparation, Not Complex Unconventional Analytics, Is Key to Meaningful Data.

Lu Y, Sweiss NJ, Macapinlac HA.

JACC Cardiovasc Imaging. 2019 Jan;12(1):217-219. doi: 10.1016/j.jcmg.2018.10.022. No abstract available.

PMID:
30621993
6.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA.

Curr Radiopharm. 2018;11(2):147-152. doi: 10.2174/1874471011666180629145030.

PMID:
29956640
7.

Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer.

Castello A, Macapinlac HA, Lopci E, Santos EB.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2256-2263. doi: 10.1007/s00259-018-4051-y. Epub 2018 May 21.

PMID:
29785515
8.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

9.

Imaging Characteristics of Chemotherapy Related Adult-Onset Still Disease.

Lu Y, Chasen BA, Macapinlac HA.

Clin Nucl Med. 2017 Dec;42(12):980-982. doi: 10.1097/RLU.0000000000001869.

PMID:
29076903
10.

Spectrum of Benign Bone Conditions on NaF-PET.

Rohren EM, Macapinlac HA.

Semin Nucl Med. 2017 Jul;47(4):392-396. doi: 10.1053/j.semnuclmed.2017.02.008. Epub 2017 Apr 18. Review.

PMID:
28583278
11.

Quantitative comparison between regularized time-of-flight and OSEM PET reconstructions for small 18F-FDG-avid lesions.

Chism CB, Ravizzini GC, Macapinlac HA, Pan T.

Nucl Med Commun. 2017 Jun;38(6):529-536. doi: 10.1097/MNM.0000000000000670.

PMID:
28383318
12.
13.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):969-978. doi: 10.1007/s00259-016-3583-2. Epub 2016 Dec 12.

14.
15.

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.

Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE 3rd, Swanston NM, Fox P, Macapinlac HA, Rohren EM.

Clin Nucl Med. 2016 Apr;41(4):268-73. doi: 10.1097/RLU.0000000000001118.

PMID:
26828141
16.

Assessing the role of ¹⁸F-FDG PET and ¹⁸F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis.

Etchebehere EC, Hobbs BP, Milton DR, Malawi O, Patel S, Benjamin RS, Macapinlac HA.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):860-70. doi: 10.1007/s00259-015-3242-z. Epub 2015 Dec 3. Review.

17.

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20. doi: 10.1007/s00259-015-3185-4. Epub 2015 Sep 29.

PMID:
26416392
18.

18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA.

Eur J Cancer. 2015 Nov;51(17):2545-52. doi: 10.1016/j.ejca.2015.07.044. Epub 2015 Aug 28.

19.

Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.

Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA.

J Nucl Med. 2015 Oct;56(10):1507-12. doi: 10.2967/jnumed.115.156026. Epub 2015 Jul 1.

20.

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM.

J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11.

21.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?

Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL.

J Thorac Oncol. 2014 Aug;9(8):1202-6. doi: 10.1097/JTO.0000000000000222.

22.

Impact of ¹⁸F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.

Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2066-73. doi: 10.1007/s00259-014-2834-3. Epub 2014 Jul 3.

PMID:
24990404
23.

The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors.

Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, Wei W, Chuang HH.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1756-66. doi: 10.1007/s00259-014-2756-0. Epub 2014 Apr 4.

PMID:
24699907
24.

Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.

Takeuchi S, Lucchini M, Schmeler KM, Coleman RL, Gershenson DM, Munsell MF, Macapinlac HA, Ramirez PT.

Gynecol Oncol. 2014 Apr;133(1):100-4. doi: 10.1016/j.ygyno.2014.02.008. Epub 2014 Feb 15.

25.

Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, Macapinlac HA.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):906-14. doi: 10.1007/s00259-013-2672-8. Epub 2014 Jan 18.

PMID:
24442598
26.

Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer.

Frumovitz M, Querleu D, Gil-Moreno A, Morice P, Jhingran A, Munsell MF, Macapinlac HA, Leblanc E, Martinez A, Ramirez PT.

J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):3-8. doi: 10.1016/j.jmig.2013.07.007. Epub 2013 Jul 31.

27.

Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG.

Ann Oncol. 2012 Oct;23(10):2638-42. Epub 2012 Jul 24.

28.

Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging.

Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A.

Int J Gynecol Cancer. 2012 Sep;22(7):1203-7. doi: 10.1097/IGC.0b013e31825e523a.

29.

Low-sensitivity FDG-PET studies: less common lung neoplasms.

Erasmus JJ, Macapinlac HA.

Semin Nucl Med. 2012 Jul;42(4):255-60. doi: 10.1053/j.semnuclmed.2012.03.001. Review.

PMID:
22681674
30.

Comparative study of the value of dual tracer PET/CT in evaluating breast cancer.

Tateishi U, Terauchi T, Akashi-Tanaka S, Kinoshita T, Kano D, Daisaki H, Murano T, Tsuda H, Macapinlac HA.

Cancer Sci. 2012 Sep;103(9):1701-7. doi: 10.1111/j.1349-7006.2012.02348.x. Epub 2012 Jul 4.

31.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA.

Blood. 2012 Jun 28;119(26):6373-8. doi: 10.1182/blood-2012-03-417808. Epub 2012 May 14.

32.

Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.

Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA.

Radiology. 2012 Apr;263(1):53-63. doi: 10.1148/radiol.12111177.

PMID:
22438441
33.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE.

Blood. 2012 May 3;119(18):4123-8. doi: 10.1182/blood-2012-01-405456. Epub 2012 Feb 27.

34.

Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality.

Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM.

J Nucl Med Technol. 2011 Jun;39(2):83-90. doi: 10.2967/jnmt.110.075283. Epub 2011 May 12.

35.

Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings.

Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM.

Cancer. 2011 May 1;117(9):1928-34. doi: 10.1002/cncr.25739. Epub 2010 Nov 16.

36.

Hybrid Modality Fusion of Planar Scintigrams and CT Topograms to Localize Sentinel Lymph Nodes in Breast Lymphoscintigraphy: Technical Description and Phantom Studies.

Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, Wendt RE 3rd.

Int J Mol Imaging. 2011;2011:298102. doi: 10.1155/2011/298102. Epub 2010 Dec 14.

37.

Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.

Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA.

Cancer. 2011 Nov 1;117(21):4823-33. doi: 10.1002/cncr.26122. Epub 2011 Mar 31.

38.

Practice based evidence of the beneficial impact of PET in patients with brain tumors.

Macapinlac HA, Czernin J, Larson SM.

Mol Imaging Biol. 2011 Feb;13(1):1-2. doi: 10.1007/s11307-010-0446-2. No abstract available.

PMID:
21082268
39.

Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.

Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, Ajani JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL.

Ann Thorac Surg. 2010 Sep;90(3):884-90; discussion 890-1. doi: 10.1016/j.athoracsur.2010.03.116.

PMID:
20732513
40.

The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.

Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA.

Oncology. 2010;78(5-6):316-22. doi: 10.1159/000319938. Epub 2010 Aug 11.

PMID:
20699623
41.

Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.

Bhosale P, Peungjesada S, Wei W, Levenback CF, Schmeler K, Rohren E, Macapinlac HA, Iyer RB.

Int J Gynecol Cancer. 2010 Aug;20(6):936-44. doi: 10.1111/IGC.0b013e3181e82a7f.

PMID:
20683399
42.

18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.

De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT.

J Nucl Med. 2010 Aug;51(8):1213-8. doi: 10.2967/jnumed.110.076455. Epub 2010 Jul 21.

43.

Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.

Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, Ajani JA.

Cancer. 2010 Oct 1;116(19):4487-94. doi: 10.1002/cncr.25431.

44.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS.

Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211. doi: 10.1016/j.bbmt.2010.06.008. Epub 2010 Jun 14. Erratum in: Biol Blood Marrow Transplant. 2010 Dec;16(12):1752. Macapintac, Homer [corrected to Macapinlac, Homer A].

45.

Incidental finding of focal FDG uptake in the bowel during PET/CT: CT features and correlation with histopathologic results.

Kei PL, Vikram R, Yeung HW, Stroehlein JR, Macapinlac HA.

AJR Am J Roentgenol. 2010 May;194(5):W401-6. doi: 10.2214/AJR.09.3703.

PMID:
20410385
46.

Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.

Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):667-74. doi: 10.1016/j.ijrobp.2009.08.063. Epub 2010 Feb 18.

47.

Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients.

Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T.

J Appl Clin Med Phys. 2010 Feb 4;11(1):3073.

48.

Acquisition parameters for oncologic imaging with a new SPECT/multislice CT scanner.

Núñez R, Erwin WD, Wendt RE 3rd, Stachowiak A, Mar M, Stevens D, Madewell JE, Yeung HW, Macapinlac HA.

Mol Imaging Biol. 2010 Apr;12(2):110-38. doi: 10.1007/s11307-009-0266-4. Epub 2010 Jan 5. Review.

PMID:
20049543
49.

NCCN task force: clinical utility of PET in a variety of tumor types.

Podoloff DA, Ball DW, Ben-Josef E, Benson AB 3rd, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ Jr, Siegel BA, Singhal S, Tyler DS, Wong RJ.

J Natl Compr Canc Netw. 2009 Jun;7 Suppl 2:S1-26. Review.

PMID:
19555588
50.

Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer.

De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2010 Jan;21(1):33-9. doi: 10.1093/annonc/mdp262. Epub 2009 Jul 14.

PMID:
19602564

Supplemental Content

Loading ...
Support Center